These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 32129773)

  • 1. Antiviral therapy and hepatocellular carcinoma risk in hepatitis B patients with cirrhosis.
    Gao X; Yang HI; Trinh H; Jeong D; Li J; Zhang J; Le A; Hoang J; Nguyen P; Henry L; Nguyen MH
    Eur J Gastroenterol Hepatol; 2020 Sep; 32(9):1207-1211. PubMed ID: 32129773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term follow-up of cumulative incidence of hepatocellular carcinoma in hepatitis B virus patients without antiviral therapy.
    Jiang XY; Huang B; Huang DP; Wei CS; Zhong WC; Peng DT; Huang FR; Tong GD
    World J Gastroenterol; 2021 Mar; 27(11):1101-1116. PubMed ID: 33776376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Risk factors for the development of liver cancer in patients with hepatitis B-related liver cirrhosis treated with long-term nucleos(t)ide analogues].
    Zang WW; Su MH; Ling XZ; Wang RM; Cao BC; Wu YL; Deng DL; Wei HL; Liang XS; Jiang JN
    Zhonghua Gan Zang Bing Za Zhi; 2020 Aug; 28(8):679-685. PubMed ID: 32911907
    [No Abstract]   [Full Text] [Related]  

  • 4. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients.
    Su TH; Hu TH; Chen CY; Huang YH; Chuang WL; Lin CC; Wang CC; Su WW; Chen MY; Peng CY; Chien RN; Huang YW; Wang HY; Lin CL; Yang SS; Chen TM; Mo LR; Hsu SJ; Tseng KC; Hsieh TY; Suk FM; Hu CT; Bair MJ; Liang CC; Lei YC; Tseng TC; Chen CL; Kao JH;
    Liver Int; 2016 Dec; 36(12):1755-1764. PubMed ID: 27634134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term prognosis with or without nucleot(s)ide analogue therapy in hepatitis B virus-related decompensated cirrhosis.
    Kumada T; Toyoda H; Yasuda S; Miyake N; Ito T; Tanaka J
    J Viral Hepat; 2021 Mar; 28(3):508-516. PubMed ID: 33306854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Entecavir and Low Genetic Barrier Antiviral Agents for Hepatocellular Carcinoma in Hepatitis B Viral Cirrhosis: Propensity Score Matching.
    Li T; Qu Y; Wang Y; Lin C; Yang B; Wang L
    J Coll Physicians Surg Pak; 2019 Apr; 29(4):317-323. PubMed ID: 30925952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Revised Korean Antiviral Guideline Reduces the Hepatitis B-related Hepatocellular Carcinoma Risk in Cirrhotic Patients.
    Kim DS; Park SY; Kim BK; Park JY; Kim DY; Han KH; Lee YR; Tak WY; Kweon YO; Jung I; Han M; Kim EH; Ahn SH; Kim SU
    J Korean Med Sci; 2021 Apr; 36(16):e105. PubMed ID: 33904261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Profile and value of FIB-4 in patients with dual chronic hepatitis C and B.
    Liu CJ; Tseng TC; Yang WT; Su TH; Yang HC; Liu CH; Chen PJ; Chen DS; Kao JH
    J Gastroenterol Hepatol; 2019 Feb; 34(2):410-417. PubMed ID: 30151861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic hepatitis B exhibited higher rate of hepatocellular carcinoma occurrence than hepatitis C in cirrhotic patients after effective antiviral treatment.
    Lin MT; Chang KC; Yen YH; Tsai MC; Chen CH; Wang JH; Hsiao CC; Chiu YH; Hu TH
    J Formos Med Assoc; 2021 Jan; 120(1 Pt 3):621-628. PubMed ID: 32718890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delayed viral suppression during antiviral therapy is associated with increased hepatocellular carcinoma rates in HBeAg-positive high viral load chronic hepatitis B.
    Nam JY; Chang Y; Cho H; Kang SH; Cho YY; Cho EJ; Lee JH; Yu SJ; Yoon JH; Kim YJ
    J Viral Hepat; 2018 May; 25(5):552-560. PubMed ID: 29194870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B.
    Kim GA; Lim YS; Han S; Choi J; Shim JH; Kim KM; Lee HC; Lee YS
    Gut; 2018 May; 67(5):945-952. PubMed ID: 29055908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective viral suppression is necessary to reduce hepatocellular carcinoma development in cirrhotic patients with chronic hepatitis B: Results of a 10-year follow up.
    Zhang W; Wang X; Wang Y; Zhao X; Duan W; Wang Q; Wu X; Kong Y; Ma H; You H; Ou X; Jia J
    Medicine (Baltimore); 2017 Nov; 96(44):e8454. PubMed ID: 29095292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.
    Papatheodoridis GV; Manolakopoulos S; Touloumi G; Vourli G; Raptopoulou-Gigi M; Vafiadis-Zoumbouli I; Vasiliadis T; Mimidis K; Gogos C; Ketikoglou I; Manesis EK;
    Gut; 2011 Aug; 60(8):1109-16. PubMed ID: 21270118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: comparison between compensated and decompensated cirrhosis.
    Kim SS; Hwang JC; Lim SG; Ahn SJ; Cheong JY; Cho SW
    Am J Gastroenterol; 2014 Aug; 109(8):1223-33. PubMed ID: 24890440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.
    Chen CJ; Yang HI; Su J; Jen CL; You SL; Lu SN; Huang GT; Iloeje UH;
    JAMA; 2006 Jan; 295(1):65-73. PubMed ID: 16391218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural history of chronic hepatitis B REVEALed.
    Chen CJ; Yang HI
    J Gastroenterol Hepatol; 2011 Apr; 26(4):628-38. PubMed ID: 21323729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stratification of hepatocellular carcinoma risk through modified FIB-4 index in chronic hepatitis B patients on entecavir therapy.
    Wang HW; Lai HC; Hu TH; Su WP; Lu SN; Lin CH; Hung CH; Chuang PH; Wang JH; Lee MH; Chen CH; Peng CY
    J Gastroenterol Hepatol; 2019 Feb; 34(2):442-449. PubMed ID: 29968933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B.
    Kim WR; Loomba R; Berg T; Aguilar Schall RE; Yee LJ; Dinh PV; Flaherty JF; Martins EB; Therneau TM; Jacobson I; Fung S; Gurel S; Buti M; Marcellin P
    Cancer; 2015 Oct; 121(20):3631-8. PubMed ID: 26177866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determinants of hepatocellular carcinoma in cirrhotic patients treated with nucleos(t)ide analogues for chronic hepatitis B.
    Hsu YC; Wu CY; Lane HY; Chang CY; Tai CM; Tseng CH; Lo GH; Perng DS; Lin JT; Mo LR
    J Antimicrob Chemother; 2014 Jul; 69(7):1920-7. PubMed ID: 24576950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognosis of Untreated Minimally Active Chronic Hepatitis B Patients in Comparison With Virological Responders by Antivirals.
    Lee HW; Kim SU; Park JY; Baatarkhuu O; Kim DY; Ahn SH; Han KH; Kim BK
    Clin Transl Gastroenterol; 2019 Jun; 10(6):e00036. PubMed ID: 31107725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.